Aquestive Therapeutics Inc (AQST)

[realfast95]

Aquestive Therapeutics price target lowered to $7 from $10 at Lake Street

Aquestive Therapeutics price target lowered to $7 from $8 at RBC Capital »

Aquestive Therapeutics price target lowered to $13 from $18 at BMO Capital 07:00 AQST BMO Capital analyst Gary Nachman lowered the firm's price target on Aquestive Therapeutics to $13 from $18 but keeps an Outperform rating on the shares. The analyst notes that the CRL for the company's key product Libervant announced by the FDA on Friday is "disappointing, but should be very fixable" in the near term. Nachman adds that Aquestive intends to resubmit the study by the end of the year and expects a PDUFA date for the drug in the first half of 2021.

Read more at:
https://thefly.com/n.php?id=3166457
Aquestive Therapeutics price target lowered to $17 from $23 at JMP

Aquestive Therapeutics price target lowered to $17 from $23 at JMP Securities 06:07 AQST JMP Securities analyst Jason Butler lowered the firm's price target on Aquestive Therapeutics to $17 from $23 but keeps an Outperform rating on the shares. The analyst notes that the company's announcement of an FDA CRL for Libervant announced on Friday is disappointing, but he believes that the path to approval remains "timely and low risk". Butler adds that his probability of approval for the drug remains at 85%, though his model pushes back assumptions for its launch and first sales by one year to 2021.

Read more at:
https://thefly.com/n.php?id=3166393Securities »

https://thefly.com/news.php?symbol=AQST